Cellestia Biotech Company

Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 successfully treating patients with multi-drug resistantcancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.

Founded Date: 2014
Investor Type: N/A
Employee Number: 1-10
Investment Stage: N/A
Funding Status: Early Stage Venture
Number Of Exists: N/A
Technology: Prevention
Industry: Gene Therapy
Headquarters: Basel